Evidence map›Paper›PMID 38472681›Full record

ArticleMolecular and cellular biochemistry2025

LncRNA MCM3AP-AS1 promotes chemoresistance in triple-negative breast cancer through the miR-524-5p/RBM39 axis.

Yueping Wang, Xuedong Wang, Haiyi Sun, Ziyun Zhang, Juan Gu

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Yueping WangDepartment of Medical Laboratory Science, Anhui No. 2 Provincial People's Hospital, 1868 #Dangshan Road, North 2nd Ring, Hefei, 230041, Anhui, China.
Xuedong WangDepartment of Medical Laboratory Science, Anhui No. 2 Provincial People's Hospital, 1868 #Dangshan Road, North 2nd Ring, Hefei, 230041, Anhui, China. wxd729@126.com.
Haiyi SunSchool of Clinical Medicine, Anhui Medical University, Hefei, 230032, Anhui, China.
Ziyun ZhangDepartment of Medical Laboratory Science, Anhui No. 2 Provincial People's Hospital, 1868 #Dangshan Road, North 2nd Ring, Hefei, 230041, Anhui, China.
Juan GuDepartment of Medical Laboratory Science, Anhui No. 2 Provincial People's Hospital, 1868 #Dangshan Road, North 2nd Ring, Hefei, 230041, Anhui, China.
Anhui Provincial Hospital · CNAnhui Medical University · CNUniversity of Connecticut · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is the most lethal subtype of BC, with unfavorable treatment outcomes. Evidence suggests the engagement of lncRNA MCM3AP-AS1 in BC development. This study investigated the action of MCM3AP-AS1 in chemoresistance of TNBC cells. Drug-resistant TNBC cell lines SUM159PT

Indexed as

Drug Resistance, NeoplasmMicroRNAsRNA-Binding ProteinsRNA, Long NoncodingTriple Negative Breast NeoplasmsAcetyltransferasesAnimalsApoptosisCell Line, TumorDoxorubicinFemaleGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsMiceMice, Inbred BALB CAcetyltransferasesDoxorubicinIntracellular Signaling Peptides and ProteinsMCM3AP protein, humanMicroRNAsMIRN-524 microRNA, humanRNA-Binding ProteinsRNA, Long NoncodingRNA, NeoplasmApoptosisceRNAChemoresistanceDoxorubicin/docetaxelMCM3AP-AS1miR-524-5pRNA binding motif 39Triple-negative breast cancer

Identifiers

PMID38472681
OpenAlexW4392693259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.